Dr. med. Patrick Schmid
Infektiologie | Infektionsprävention | Reisemedizin · Dept. I
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile
Metral M, Monsch A, Kunze U, Stoeckle M, Schwind M, Schmid P, Pignatti R, Di Benedetto C, Du Pasquier R, Cavassini M, NAMACO study group, Assal F, Lecompte T, Darling K, Locatelli I, Nadin I, Santos G, Brugger P, Kovari H, Cusini A, Gutbrod K, Tarr P, Calmy A, Swiss HIV Cohort Study. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile. HIV Med 2019; 21:30-42.
07.10.2019The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile
07.10.2019HIV Med 2019; 21:30-42
Metral M, Monsch A, Kunze U, Stoeckle M, Schwind M, Schmid Patrick, Pignatti R, Di Benedetto C, Du Pasquier R, Cavassini M, NAMACO study group, Assal F, Lecompte T D, Darling Kea, Locatelli I, Nadin I, Santos G, Brugger P, Kovari H, Cusini A, Gutbrod K, Tarr P E, Calmy A, Swiss HIV Cohort Study
Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis
Künzler-Heule P, Nicca D, Fehr J, Braun D, Rougement M, Flepp M, Schmid P, Delaloye J, Béguelin C, Stöckle M, Hampel B, Nöstlinger C, Kocher A, Nguyen H, Fierz K, Schmidt A, Battegay M, Engberg S, Swiss HIV Cohort Study (SHCS). Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. BMC Infect Dis 2019; 19:821.
18.09.2019Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis
18.09.2019BMC Infect Dis 2019; 19:821
Künzler-Heule Patrizia, Nicca Dunja, Fehr Jan, Braun Dominique Laurent, Rougement Mathieu, Flepp Markus, Schmid Patrick, Delaloye Julie, Béguelin Charles, Stöckle Marcel, Hampel Benjamin, Nöstlinger Christiana, Kocher Agnes, Nguyen Huyen, Fierz Katharina, Schmidt Axel J, Battegay Manuel, Engberg Sandra, Swiss HIV Cohort Study (SHCS)
Self-reported neurocognitive impairment in people living with HIV: Characterizing clusters of patients with similar changes in self-reported neurocognitive impairment 2013-2017 in the Swiss HIV Cohort Study
Kusejko K, Kouyos R, Günthard H, Hauser C, Du Pasquier R, Schmid P, Cavassini M, Doco-Lecompte T, Bernasconi E, Tarr P, Braun D, Salazar-Vizcaya L, Swiss HIV Cohort Study. Self-reported neurocognitive impairment in people living with HIV: Characterizing clusters of patients with similar changes in self-reported neurocognitive impairment 2013-2017 in the Swiss HIV Cohort Study. Clin Infect Dis 2019
03.09.2019Self-reported neurocognitive impairment in people living with HIV: Characterizing clusters of patients with similar changes in self-reported neurocognitive impairment 2013-2017 in the Swiss HIV Cohort Study
03.09.2019Clin Infect Dis 2019
Kusejko Katharina, Kouyos Roger D, Günthard Huldrych F, Hauser Christoph, Du Pasquier Renaud, Schmid Patrick, Cavassini Matthias, Doco-Lecompte Thanh, Bernasconi Enos, Tarr Philip E, Braun Dominique L, Salazar-Vizcaya Luisa, Swiss HIV Cohort Study
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
Olearo F, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Boeni J, Bernasconi E, Günthard H, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagiola D, Schmid P, Calmy A. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infect Dis 2019; 6:ofz330.
12.07.2019Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
12.07.2019Open Forum Infect Dis 2019; 6:ofz330
Olearo Flaminia, D'arminio Monforte Antonella, Zazzi Maurizio, Rossetti Barbara, Neau Didier, Bellecave Pantxika, Rijnders Bart, Reiss Peter, Wit Ferdinand, Kouyos Roger, Boeni Jürg, Bernasconi Enos, Günthard Huldrych F, Nguyen Huyen, Bonnet Fabrice, Yerly Sabine, Wandeler Gilles, Stoeckle Marcel, Cavassini Matthias, Scherrer Alexandra, Costagiola Dominique, Schmid Patrick, Calmy Alexandra
Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland
Santos G, Cavassini M, Du Pasquier R, Darling K, Schmid P, Di Benedetto C, Fux C, Stoeckle M, Tarr P, Kovari H, Hasse B, Cusini A, Hauser C, Nadin I, Lecompte T, Calmy A, Métral M, Locatelli I, Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Group. Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. Open Forum Infect Dis 2019; 6:ofz277.
08.07.2019Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland
08.07.2019Open Forum Infect Dis 2019; 6:ofz277
Santos Galia M A, Cavassini Matthias, Du Pasquier Renaud, Darling Katharine E A, Schmid Patrick, Di Benedetto Caroline, Fux Christoph, Stoeckle Marcel, Tarr Philip, Kovari Helen, Hasse Barbara, Cusini Alexia, Hauser Christoph, Nadin Isaure, Lecompte Thanh Doco, Calmy Alexandra, Métral Mélanie, Locatelli Isabella, Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Group
Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?
Bertisch B, Keiser O, Moradpour D, Zehnder C, Marinucci F, Roelens M, Moriggia A, Clerc O, Giudici F, Schmid P, Künzler-Heule P, Ottiger C, Mullhaupt B, Negro F, Brezzi M, Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?. Clin Infect Dis 2019
03.04.2019Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?
03.04.2019Clin Infect Dis 2019
Bertisch Barbara, Keiser Olivia, Moradpour Darius, Zehnder Cinzia, Marinucci Francesco, Roelens Maroussia, Moriggia Alberto, Clerc Olivier, Giudici Fabio, Schmid Patrick, Künzler-Heule Patrizia, Ottiger Cornelia, Mullhaupt Beat, Negro Francesco, Brezzi Matteo, Swiss Hepatitis C Cohort Study
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy 2018; 62:94-103.
29.10.2018Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
29.10.2018Int J Drug Policy 2018; 62:94-103
Grebely Jason, Feld Jordan J, Bruneau Julie, Daulouede Jean-Pierre, Powis Jeff, Bruggmann Philip, Matthews Gail V, Kronborg Ian, Shaw David, Dunlop Adrian, Hellard Margaret, Applegate Tanya L, Crawford Sione, Dore Gregory J, Lacombe Karine, Dalgard Olav, Conway Brian, Cunningham Evan B, Fraser Chris, Moriggia Alberto, Gane Ed, Stedman Catherine, Cooper Curtis, Castro Erika, Schmid Patrick, Petoumenos Kathy, Hajarizadeh Behzad, Marks Phillipa, Erratt Amanda, D3FEAT Study Group
Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations
Laut K, Schmid P, Kuzovatova E, Paduta D, Smidt J, Domingo P, Szlávik J, Lundgren J, Mocroft A, Kirk O, Mulcahy F, Fätkenheuer G, Ristola M, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, Begovac J, Radoi R, Schmied B, Chkhartishvili N, Florence E, EuroSIDA Study Group. Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations. AIDS 2018
04.10.2018Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations
04.10.2018AIDS 2018
Laut Kamilla Grønborg, Schmid Patrick, Kuzovatova Elena, Paduta Dzmitry, Smidt Jelena, Domingo Pere, Szlávik Janos, Lundgren Jens, Mocroft Amanda, Kirk Ole, Mulcahy Fiona, Fätkenheuer Gerd, Ristola Matti, Shepherd Leah, Gottfredsson Magnus, Sedlacek Dalibor, Knysz Brygida, Begovac Josip, Radoi Roxana, Schmied Brigitte, Chkhartishvili Nikoloz, Florence Eric, EuroSIDA Study Group
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
Conconi A, Bernasconi E, Bertoni F, Gaidano G, Cavalli F, Nassi L, Kwee I, Dirnhofer S, Scherrer A, Schmid P, Novak U, Staehelin C, Battegay M, Hasse B, Darling K, Margiotta-Casaluci G, Zucca E, Swiss HIV Cohort Study (SHCS). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematol Oncol 2018
16.08.2018Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
16.08.2018Hematol Oncol 2018
Conconi Annarita, Bernasconi Enos, Bertoni Francesco, Gaidano Gianluca, Cavalli Franco, Nassi Luca, Kwee Ivo, Dirnhofer Stephan, Scherrer Alexandra, Schmid Patrick, Novak Urban, Staehelin Cornelia, Battegay Manuel, Hasse Barbara, Darling Katharine, Margiotta-Casaluci Gloria, Zucca Emanuele, Swiss HIV Cohort Study (SHCS)
High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men
Braun D, Fehr J, Böni J, Günthard H, Rauch A, Bernasconi E, Rougemont M, Delaloye J, Schmid P, Béguelin C, Conen A, Stöckle M, Flepp M, Grube C, Kusejko K, Kouyos R, Martin E, Hampel B, Swiss HIV Cohort Study. High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men. Clin Infect Dis 2018
13.08.2018High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men
13.08.2018Clin Infect Dis 2018
Braun Dominique L, Fehr Jan S, Böni Jürg, Günthard Huldrych F, Rauch Andri, Bernasconi Enos, Rougemont Mathieu, Delaloye Julie, Schmid Patrick, Béguelin Charles, Conen Anna, Stöckle Marcel, Flepp Markus, Grube Christina, Kusejko Katharina, Kouyos Roger, Martin Eileen, Hampel Benjamin, Swiss HIV Cohort Study
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men
Braun D, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard H, Böni J, Fehr J, Nicca D, Künzler-Heule P, Hampel B, Kouyos R, Nguyen H, Shah C, Flepp M, Stöckle M, Conen A, Béguelin C, Swiss HIV Cohort Study. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis 2018
13.08.2018High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men
13.08.2018Clin Infect Dis 2018
Braun Dominique L, Schmid Patrick, Delaloye Julie, Rougemont Mathieu, Bernasconi Enos, Rauch Andri, Günthard Huldrych F, Böni Jürg, Fehr Jan S, Nicca Dunja, Künzler-Heule Patrizia, Hampel Benjamin, Kouyos Roger, Nguyen Huyen, Shah Cyril, Flepp Markus, Stöckle Marcel, Conen Anna, Béguelin Charles, Swiss HIV Cohort Study
Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons
Reinschmidt S, Kovari H, Buechel R, Kaufmann P, Weber R, Schmid P, Hauser C, Kouyos R, Tarr P, Turk T, Swiss HIV Cohort Study. Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons. Open Forum Infect Dis 2018; 5:ofy084.
20.04.2018Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons
20.04.2018Open Forum Infect Dis 2018; 5:ofy084
Reinschmidt Sara, Kovari Helen, Buechel Ronny R, Kaufmann Philipp, Weber Rainer, Schmid Patrick, Hauser Christoph, Kouyos Roger, Tarr Philip E, Turk Teja, Swiss HIV Cohort Study
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
Santos J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren J, Bogner J, Duvivier C, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, EuroSIDA Study Group. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. HIV Med 2018; 19:324-338.
01.02.2018Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
01.02.2018HIV Med 2018; 19:324-338
Santos J R, Gargalianos-Kakolyris P, Schmid Patrick, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren J D, Bogner J, Duvivier C, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, EuroSIDA Study Group
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity
Bertels F, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer A, Müller V, Bonhoeffer S, Kouyos R, Regoes R, Rauch A, Battegay M, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard H, Böni J, Yerly S, Klimkait T, Aubert V, Swiss HIV Cohort Study. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Mol Biol Evol 2018; 35:27-37.
01.01.2018Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity
01.01.2018Mol Biol Evol 2018; 35:27-37
Bertels Frederic, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Schmid Patrick, Scherrer Alexandra U, Müller Viktor, Bonhoeffer Sebastian, Kouyos Roger, Regoes Roland R, Rauch Andri, Battegay Manuel, Marzel Alex, Leventhal Gabriel, Mitov Venelin, Fellay Jacques, Günthard Huldrych F, Böni Jürg, Yerly Sabine, Klimkait Thomas, Aubert Vincent, Swiss HIV Cohort Study
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly 2017; 147:w14543.
09.11.2017Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
09.11.2017Swiss Med Wkly 2017; 147:w14543
Bruggmann Philip, Stoeckle Marcel, Semela David, Schmid Patrick, Razavi Homie, Rauch Andri, Mullhaupt Beat, Lavanchy Daniel, Kouyos Roger, Fehr Jan, Deltenre Pierre, Blach Sarah, Negro Franco
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
Cozzi-Lepri A, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso M, Lundgren J, Mocroft A, Gottfredsson M, Schmid P, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med 2017
06.10.2017Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
06.10.2017HIV Med 2017
Cozzi-Lepri A, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso M H, Lundgren J D, Mocroft A, Gottfredsson M, Schmid Patrick, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, EuroSIDA Study Group
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis
Yerly S, Marzolini C, Martinez de Tejada B, Martinetti G, Ledergerber B, Kovari H, Kouyos R, Klimkait T, Keiser O, Kaiser L, Kahlert C, Hösli I, Hoffmann M, Hirsch H, Hasse B, Metzner K, Müller N, Weber R, Wandeler G, Vernazza P, Trkola A, Tarr P, Stöckle M, Speck R, Schmid P, Scherrer A, Rudin C, Rauch A, Paioni P, Pantaleo G, Nicca D, Haerry D, Günthard H, Fux C, Kouyos R, Günthard H, Hoffmann M, Furrer H, Cavassini M, Calmy A, Bernasconi E, Battegay M, Klimkait T, Aubert V, Yerly S, Böni J, Kadelka C, Bachmann N, Swiss HIV Cohort Study, Aubert V, Furrer H, Fellay J, Fehr J, Elzi L, Egger M, Dollenmaier G, Ciuffi A, Cavassini M, Calmy A, Bucher H, Braun D, Böni J, Bernasconi E, Battegay M, Turk T. Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. Elife 2017; 6
12.09.2017Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis
12.09.2017Elife 2017; 6
Yerly S, Marzolini C, Martinez de Tejada B, Martinetti G, Ledergerber B, Kovari H, Kouyos R D, Klimkait T, Keiser O, Kaiser L, Kahlert Christian, Hösli I, Hoffmann M, Hirsch H H, Hasse B, Metzner K J, Müller N, Weber R, Wandeler G, Vernazza Pietro, Trkola A, Tarr P, Stöckle M, Speck R, Schmid Patrick, Scherrer A U, Rudin C, Rauch A, Paioni P, Pantaleo G, Nicca D, Haerry D, Günthard H F, Fux C A, Kouyos Roger D, Günthard Huldrych F, Hoffmann Matthias, Furrer Hansjakob, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Battegay Manuel, Klimkait Thomas, Aubert Vincent, Yerly Sabine, Böni Jürg, Kadelka Claus, Bachmann Nadine, Swiss HIV Cohort Study, Aubert V, Furrer H, Fellay J, Fehr J, Elzi L, Egger M, Dollenmaier G, Ciuffi A, Cavassini M, Calmy A, Bucher H C, Braun D L, Böni J, Bernasconi E, Battegay M, Turk Teja
On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study
Salazar-Vizcaya L, Rauch A, Keiser O, Günthard H, Wandeler G, Rougemont M, Schmid P, Stöckle M, Delaloye J, Bernasconi E, Estill J, Braun D, Fehr J, Kouyos R, Swiss HIV Cohort Study. On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study. J Viral Hepat 2017; 25:10-18.
23.08.2017On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study
23.08.2017J Viral Hepat 2017; 25:10-18
Salazar-Vizcaya L, Rauch A, Keiser O, Günthard H F, Wandeler G, Rougemont M, Schmid Patrick, Stöckle M, Delaloye J, Bernasconi E, Estill J, Braun D, Fehr J, Kouyos R D, Swiss HIV Cohort Study
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study
Béguelin C, Rauch A, Wandeler G, Schmid P, Rougemont M, Cavassini M, Stoeckle M, Bucher H, Kovari H, Fehr J, Bernasconi E, Suter A, Swiss HIV Cohort Study. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver Int 2017
25.07.2017Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study
25.07.2017Liver Int 2017
Béguelin Charles, Rauch Andri, Wandeler Gilles, Schmid Patrick, Rougemont Mathieu, Cavassini Mathias, Stoeckle Marcel, Bucher Heiner C, Kovari Helen, Fehr Jan, Bernasconi Enos, Suter Annatina, Swiss HIV Cohort Study
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
Sculier D, Calmy A, Bernasconi E, Schmid P, Hirzel C, Fehr J, Cavassini M, Battegay M, Gayet-Ageron A, Swiss HIV Cohort Study. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis 2017; 17:476.
06.07.2017Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
06.07.2017BMC Infect Dis 2017; 17:476
Sculier Delphine, Calmy Alexandra, Bernasconi Enos, Schmid Patrick, Hirzel Cédric, Fehr Jan, Cavassini Matthias, Battegay Manuel, Gayet-Ageron Angèle, Swiss HIV Cohort Study